These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 25281710)

  • 1. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
    Zhou Q; Cheng Y; Yang JJ; Zhao MF; Zhang L; Zhang XC; Chen ZH; Yan HH; Song Y; Chen JH; Feng WN; Xu CR; Wang Z; Chen HJ; Zhong WZ; Liu YP; Wu YL
    Ann Oncol; 2014 Dec; 25(12):2385-2391. PubMed ID: 25281710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
    Yang JC; Kang JH; Mok T; Ahn MJ; Srimuninnimit V; Lin CC; Kim DW; Tsai CM; Barraclough H; Altug S; Orlando M; Park K
    Eur J Cancer; 2014 Sep; 50(13):2219-30. PubMed ID: 24953333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
    Yang JC; Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Hozak RR; Nguyen TS; Zhang WL; Enatsu S; Puri T; Orlando M
    J Thorac Oncol; 2020 Jan; 15(1):91-100. PubMed ID: 31605797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
    Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
    Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
    Yu H; Zhang J; Wu X; Luo Z; Wang H; Sun S; Peng W; Qiao J; Feng Y; Wang J; Chang J
    Cancer Biol Ther; 2014 Jul; 15(7):832-9. PubMed ID: 24755888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.
    Kim YS; Cho EK; Woo HS; Hong J; Ahn HK; Park I; Sym SJ; Kyung SY; Kang SM; Park JW; Jeong SH; Park J; Lee JH; Shin DB
    Cancer Res Treat; 2016 Jan; 48(1):80-7. PubMed ID: 25761488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
    Noronha V; Patil VM; Joshi A; Menon N; Chougule A; Mahajan A; Janu A; Purandare N; Kumar R; More S; Goud S; Kadam N; Daware N; Bhattacharjee A; Shah S; Yadav A; Trivedi V; Behel V; Dutt A; Banavali SD; Prabhash K
    J Clin Oncol; 2020 Jan; 38(2):124-136. PubMed ID: 31411950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study.
    Yang JC; Srimuninnimit V; Ahn MJ; Lin CC; Kim SW; Tsai CM; Mok T; Orlando M; Puri T; Wang X; Park K
    J Thorac Oncol; 2016 Mar; 11(3):370-9. PubMed ID: 26725183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
    Shi YK; Wang L; Han BH; Li W; Yu P; Liu YP; Ding CM; Song X; Ma ZY; Ren XL; Feng JF; Zhang HL; Chen GY; Han XH; Wu N; Yao C; Song Y; Zhang SC; Song W; Liu XQ; Zhao SJ; Lin YC; Ye XQ; Li K; Shu YQ; Ding LM; Tan FL; Sun Y
    Ann Oncol; 2017 Oct; 28(10):2443-2450. PubMed ID: 28945850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
    Boye M; Wang X; Srimuninnimit V; Kang JH; Tsai CM; Orlando M; Puri T; Kim JS; Rajan N; Yang JC
    Clin Lung Cancer; 2016 Mar; 17(2):150-60. PubMed ID: 26809984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
    Ahn MJ; Yang JC; Liang J; Kang JH; Xiu Q; Chen YM; Blair JM; Peng G; Linn C; Orlando M
    Lung Cancer; 2012 Aug; 77(2):346-52. PubMed ID: 22534669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
    Li T; Piperdi B; Walsh WV; Kim M; Beckett LA; Gucalp R; Haigentz M; Bathini VG; Wen H; Zhou K; Pasquinelli PB; Gajavelli S; Sreedhara M; Xie X; Lara PN; Gandara DR; Perez-Soler R
    Clin Lung Cancer; 2017 Jan; 18(1):60-67. PubMed ID: 27919627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.